title: Pathogenesis of prostate cancer: lessons from basic research.
abstract: In the United States, prostate cancer is the second most common cause of cancer-related deaths in men. While the importance of androgens and androgen receptors (ARs) in primary prostate cancer is well established, the role of ARs in prostate cancers that emerge despite androgen ablation therapies remains poorly understood. The aim of this article is to illustrate the fundamental biology of prostate cancer. We focus mainly on the AR because of its critical role in the progression and metastatic spread of prostate cancer. We also summarize the alternate pathways that may potentially contribute to the progression of prostate cancer. Identifying the underlying mechanisms of androgen independence is crucial in the design of appropriate therapies for hormone-refractory neoplasms.
authors: Vamsidhar
authors: V
authors: Velcheti
authors: Satish
authors: S
authors: Karnik
authors: Stephen F
authors: SF
authors: Bardot
authors: Om
authors: O
authors: Prakash
references: Lab Invest. 2001 Dec;81(12):1647-51
references: 11742035
references: Nucl Recept Signal. 2008 Feb 01;6:e001
references: 18301781
references: Endocr Relat Cancer. 2005 Dec;12(4):983-98
references: 16322337
references: Urol Clin North Am. 1997 May;24(2):421-31
references: 9126240
references: Cancer Res. 2001 Apr 1;61(7):2892-8
references: 11306464
references: Cancer Res. 1993 Jul 15;53(14):3369-73
references: 8324747
references: Urology. 2001 Nov;58(5):651-6
references: 11711330
references: J Urol. 2000 Dec;164(6):1992-5
references: 11061898
references: Hum Pathol. 2005 Nov;36(11):1186-96
references: 16260272
references: Endocr Relat Cancer. 2008 Dec;15(4):841-9
references: 18667687
references: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references: 18287387
references: Cancer Res. 2004 Feb 1;64(3):1058-66
references: 14871838
references: J Cell Biochem. 2006 Oct 1;99(2):362-72
references: 16619264
references: J Urol. 2008 Sep;180(3):921-7
references: 18635218
references: J Cancer Res Clin Oncol. 2004 Oct;130(10):604-14
references: 15258753
references: Cancer Res. 2002 Nov 15;62(22):6659-66
references: 12438264
references: J Urol. 1998 Jan;159(1):149-53
references: 9400459
references: Vitam Horm. 2002;65:127-47
references: 12481545
references: Cell Cycle. 2008 Mar 1;7(5):631-6
references: 18256541
references: J Clin Oncol. 2002 Jul 1;20(13):3001-15
references: 12089231
references: Cell Cycle. 2008 Jun 15;7(12):1745-62
references: 18594202
references: Prostate. 1996 Apr;28(4):251-65
references: 8602401
references: Neoplasia. 2007 Feb;9(2):90-100
references: 17357254
references: Mol Cell Endocrinol. 2007 May 30;270(1-2):50-6
references: 17374439
references: Int J Cancer. 2007 Feb 15;120(4):719-33
references: 17163421
references: J Urol. 1993 Mar;149(3):607-9
references: 7679759
references: Nat Genet. 1995 Apr;9(4):401-6
references: 7795646
references: Nat Med. 2004 Jan;10(1):33-9
references: 14702632
references: Clin Cancer Res. 2000 Jul;6(7):2702-6
references: 10914713
references: Cancer Res. 2005 Apr 15;65(8):2990-2
references: 15833820
references: Cancer Res. 2000 Feb 15;60(4):944-9
references: 10706109
references: BJU Int. 2005 Jun;95(9):1320-6
references: 15892825
references: Ann Oncol. 2007 Nov;18(11):1765-73
references: 17426060
references: J Clin Oncol. 2005 Nov 10;23(32):8253-61
references: 16278481
references: Cancer Res. 1994 Oct 15;54(20):5474-8
references: 7522959
references: Carcinogenesis. 2006 Jan;27(1):1-22
references: 16195239
references: Prostate. 2007 Jan 1;67(1):32-40
references: 16998819
references: Prostate Cancer Prostatic Dis. 2005;8(2):119-26
references: 15809669
references: J Cell Biochem. 2004 Jan 1;91(1):3-12
references: 14689576
references: J Cell Biochem. 2005 Jun 1;95(3):497-505
references: 15838876
references: Cancer Res. 1999 Sep 1;59(17):4291-6
references: 10485474
references: Cancer Res. 1999 Jun 1;59(11):2511-5
references: 10363963
references: Cancer Res. 2008 May 1;68(9):3323-33
references: 18451159